Aclaris Therapeutics (ACRS) News Today $2.57 +0.06 (+2.39%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Jane Street Group LLC Reduces Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Jane Street Group LLC reduced its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 75.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 82,727 shares of the biotechnology company's stock after selling 252,282 sJanuary 15 at 3:08 AM | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of "Buy" by AnalystsJanuary 13, 2025 | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommeJanuary 13, 2025 | marketbeat.comHead-To-Head Survey: Appili Therapeutics (OTCMKTS:APLIF) versus Aclaris Therapeutics (NASDAQ:ACRS)January 13, 2025 | americanbankingnews.comAclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 6, 2025 | globenewswire.comShort Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 27.4%Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 3,160,000 shares, an increase of 27.4% from the November 30th total of 2,480,000 shares. Based on an average trading volume of 2,330,000 shares, the short-interest ratio is currently 1.4 days.December 29, 2024 | marketbeat.comHC Wainwright Has Strong Forecast for ACRS FY2024 EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Investment analysts at HC Wainwright increased their FY2024 earnings estimates for shares of Aclaris Therapeutics in a note issued to investors on Monday, December 23rd. HC Wainwright analyst R. Selvaraju now expects that the biotechnologyDecember 25, 2024 | marketbeat.comAclaris Therapeutics’ Strategic Licensing and Promising Pipeline Drive Buy RecommendationDecember 23, 2024 | markets.businessinsider.comAclaris Therapeutics upgraded to Buy from Neutral at H.C. WainwrightDecember 23, 2024 | markets.businessinsider.comHC Wainwright & Co. Upgrades Aclaris Therapeutics (ACRS)December 23, 2024 | msn.comAclaris Therapeutics (NASDAQ:ACRS) Upgraded at HC WainwrightHC Wainwright upgraded Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 price objective for the company in a report on Monday.December 23, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Buy" by BrokeragesAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issueDecember 19, 2024 | marketbeat.comAclaris Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy RatingDecember 18, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Hold on Aclaris Therapeutics (ACRS)December 17, 2024 | markets.businessinsider.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short InterestAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 2,480,000 shares, an increase of 59.0% from the November 15th total of 1,560,000 shares. Based on an average trading volume of 2,210,000 shares, the short-interest ratio is currently 1.1 days.December 12, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Takes $1.05 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Jacobs Levy Equity Management Inc. bought a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 915,509 shareDecember 9, 2024 | marketbeat.comAclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement PlanDecember 5, 2024 | msn.comAclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comAclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceDecember 1, 2024 | msn.comConnor Clark & Lunn Investment Management Ltd. Boosts Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 187.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 332,406 shares of the bioteDecember 1, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Decrease in Short InterestAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 1,560,000 shares, a decrease of 35.3% from the October 31st total of 2,410,000 shares. Based on an average daily volume of 2,110,000 shares, the days-to-cover ratio is presently 0.7 days.November 28, 2024 | marketbeat.comAclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | globenewswire.comCantor Fitzgerald Issues Positive Outlook for ACRS EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for Aclaris Therapeutics in a report released on Thursday, November 21st. Cantor Fitzgerald analyst L. Chen now anticipates that the biotechnology company wilNovember 25, 2024 | marketbeat.comAclaris Therapeutics Share Price (ACRS.US)November 24, 2024 | lse.co.ukAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by BrokeragesAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned an average rating of "Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has asNovember 24, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Director Anand Mehra Acquires 666,666 SharesNovember 21, 2024 | insidertrades.comEquities Analysts Offer Predictions for ACRS FY2024 EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2024 earnings estimates for Aclaris Therapeutics in a research note issued on Tuesday, November 19th. Leerink Partnrs analyst T. Smith now forecasts that the biotechnology company willNovember 21, 2024 | marketbeat.comAclaris Therapeutics upgraded to Buy from Hold at JefferiesNovember 21, 2024 | finance.yahoo.comJefferies Upgrades Aclaris Therapeutics (ACRS)November 21, 2024 | msn.comAclaris Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldNovember 20, 2024 | markets.businessinsider.comAclaris upgraded at Cantor after deal adds two ‘potential blockbusters’November 20, 2024 | markets.businessinsider.comLeerink Partners Upgrades Aclaris Therapeutics (ACRS)November 20, 2024 | msn.comAclaris upgraded to overweight by Cantor on in-licensing dealNovember 20, 2024 | msn.comBTIG Upgrades Aclaris Therapeutics (ACRS)November 20, 2024 | msn.comPromising Potential of Aclaris Therapeutics’ BSI-045B and Pipeline Elevates Buy RatingNovember 20, 2024 | markets.businessinsider.comLeerink Partnrs Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Strong-BuyLeerink Partnrs raised shares of Aclaris Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday.November 20, 2024 | marketbeat.comAclaris Therapeutics Positioned for Growth with Strategic Acquisition and Promising PipelineNovember 20, 2024 | markets.businessinsider.comAclaris Therapeutics upgraded to Outperform from Market Perform at LeerinkNovember 20, 2024 | markets.businessinsider.comAclaris stock soars for second day on licensing deal, analyst upgradesNovember 20, 2024 | msn.comAclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline DevelopmentsNovember 19, 2024 | benzinga.comAclaris Therapeutics (NASDAQ:ACRS) Upgraded at Leerink PartnersLeerink Partners raised Aclaris Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $2.00 to $7.00 in a research note on Tuesday.November 19, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Raised to Buy at Jefferies Financial GroupJefferies Financial Group raised shares of Aclaris Therapeutics from a "hold" rating to a "buy" rating and upped their target price for the company from $2.00 to $7.00 in a report on Tuesday.November 19, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Buy at BTIG ResearchBTIG Research raised shares of Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $8.00 price objective on the stock in a research note on Tuesday.November 19, 2024 | marketbeat.comAclaris Therapeutics: Promising Pipeline Developments and Strategic Acquisitions Bolster Buy RatingNovember 19, 2024 | markets.businessinsider.comAclaris Therapeutics upgraded to Buy from Neutral at BTIGNovember 19, 2024 | markets.businessinsider.comAclaris Therapeutics Expands Pipeline and Strengthens LeadershipNovember 18, 2024 | markets.businessinsider.comAclaris stock rallies 53% amid licensing deal, Piper upgradeNovember 18, 2024 | msn.comAclaris Therapeutics upgraded to Overweight from Neutral at Piper SandlerNovember 18, 2024 | markets.businessinsider.comBiosion Inks Exclusive Deal With Aclaris For Worldwide Rights To BSI-045B And BSI-502November 18, 2024 | markets.businessinsider.comAclaris shares surge on licensing deal valued at up to nearly $1 billionNovember 18, 2024 | bizjournals.com Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRS Media Mentions By Week ACRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼0.580.72▲Average Medical News Sentiment ACRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼52▲ACRS Articles Average Week Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prothena News Today Bicara Therapeutics News Today CorMedix News Today uniQure News Today 89bio News Today Dianthus Therapeutics News Today Cullinan Therapeutics News Today Pharming Group News Today Arbutus Biopharma News Today LENZ Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
